Regeneron Invest Information

Financial Advocates Investment Management Acquires Shares of Regeneron Pharmaceuticals, Inc. Feb 9, 2025

Dupixent® (dupilumab) Receives U.S. Approval for Treating Chronic Rhinosinusitis with Nasal Polyps in Adolescents Sep 14, 2024

Regeneron Showcases Respiratory Treatments at ERS 2024 Congress Aug 26, 2024

Innovative COPD Therapy Dupixent Gains Approval in the EU, Marking a First for Targeted Treatment Jul 4, 2024

Intellia Therapeutics Surpasses Q3 Earnings Expectations and Announces Progress in Gene-Editing Pipeline Nov 11, 2023